
Opinion|Videos|August 16, 2024
The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.
Advertisement
Episodes in this series

- How do androgen receptor-targeted therapies, including abiraterone and enzalutamide, fit into the treatment paradigm, and when might you choose an androgen receptor-targeted therapy over other treatment options, or vice versa?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
2
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
3
FDA greenlights phase 1 study of UGN-501 for NMIBC
4
Urocross shows sustained benefit through 24 months post-removal
5













